title: Pentostatin in T-cell malignancies--a phase II trial of the EORTC. Leukemia Cooperative Group.
abstract: OBJECTIVE
  Within this phase II EORTC trial, we have investigated the safety and efficacy of pentostatin in lymphoid malignancies. We have previously reported the results in T- and B-cell prolymphocytic leukemia, B-cell chronic lymphocytic leukemia (B-CLL) and hairy cell leukemia. This report focuses on the outcome in T-cell malignancies: T-CLL, Sézary syndrome (Sézary), mycosis fungoides (MF) and T-zone lymphoma (TZL).
  
  
  METHODS
  Of the 92 patients with these diagnoses enrolled, 76 were evaluable for response and toxicity, i.e., 25 of 28 with T-CLL, 21 of 26 with Sézary, 22 of 26 with MF, and 8 of 12 with TZL. All patients had progressive and advanced disease. Pentostatin was administered at a dosage of 4 mg/m2 every week for the first 3 weeks, then 4 mg/m2 every 14 days for another 6 weeks, followed by maintenance therapy of 4 mg/m2 monthly for a maximum of 6 months.
  
  
  RESULTS
  Response rates (complete and partial responses) in patients with Sézary (n = 22) or MF (n = 21) were 33% and 23%, respectively, and in patients with T-CLL (n = 21) or TZL (n = 8) 8% and 25%, respectively. Sixteen (21%) patients died during the first ten weeks of treatment: twelve of progressive disease, two of infectious complications with progressive disease, one of myocard infarction and one of renal failure related to administration of i.v. contrast. Major toxicity (grade 3-4) included infection in 11% of patients, nausea/vomiting in 4%, diarrhea in 3%. Hematologic toxicity was mild to non-existent.
  
  
  CONCLUSIONS
  We conclude that pentostatin is active in Sézary and MF but showed marginal activity in T-CLL or TZL. Toxicities are mild to moderate at the dose schedule administered. Due to its relatively specific lympholytic effect and its favorable toxicity spectrum, pentostatin might be especially useful for the palliative treatment of T-cell malignancies.
authors.affiliation: Department of Medicine V, University of Heidelberg, Germany. anthony.ho@med.uni-heidelberg.de
authors.forename: A D
authors.initials: AD
authors.lastname: Ho
authors.forename: S
authors.initials: S
authors.lastname: Suciu
authors.forename: P
authors.initials: P
authors.lastname: Stryckmans
authors.forename: F
authors.initials: F
authors.lastname: De Cataldo
authors.forename: R
authors.initials: R
authors.lastname: Willemze
authors.forename: J
authors.initials: J
authors.lastname: Thaler
authors.forename: M
authors.initials: M
authors.lastname: Peetermans
authors.forename: H
authors.initials: H
authors.lastname: Döhner
authors.forename: G
authors.initials: G
authors.lastname: Solbu
authors.forename: M
authors.initials: M
authors.lastname: Dardenne
authors.forename: R
authors.initials: R
authors.lastname: Zittoun
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015649:Pentostatin / Q000627:therapeutic use*; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000903:Antibiotics, Antineoplastic; D015649:Pentostatin